Pharmaceuticals, Biotechnology and Life Sciences
Positive Phase 1 data from lead program, SENTI-202, recently presented at the AACR Annual Meeting: SENTI-202 was generally well tolerated,…
Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2025…
NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company…
ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction TodayACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today LOS…
THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will…
Advancement of lead candidate BGE-102, an oral, brain-penetrant NLRP3 inhibitor for obesity, with initial clinical data expected 2H25New strategic collaboration…
ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) — MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and…
WESTLAKE VILLAGE, Calif., May 06, 2025 (GLOBE NEWSWIRE) — Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced…
First quarter 2025 net sales of Qelbree® increased 44% to $64.7 million, compared to the same period in 2024.First quarter…
Highlights First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds1 of $16 million, revenue increased 5% year-over-year.First…